Late-Breaking Data Confirms Safety of Axon Therapies' Innovative Heart Failure Procedure and Identifies Patients Most Likely to Benefit from SAVM Therapy
REBALANCE-HF early feasibility trial met objective of identifying responder group with demonstrated benefits in heart function, hemodynamics, and physical activity at 6 months
United States Sanjiv Shah Bluhm Cardiovascular Institute Duke University Heart Failure Society Of America Feinberg School Of Medicine
Source: dicardiology.com